Vertex Pharmaceuticals
50 Northern Ave
Boston
Massachusetts
02210
United States
Tel: 617-341-6100
Website: http://www.vrtx.com/
740 articles with Vertex Pharmaceuticals
-
In October, Vertex Pharmaceuticals announced stunning results in a type 1 diabetes patient who had been dosed with the company’s experimental therapy.
-
Vertex Announces Reimbursement Agreement in Spain for KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in Combination With Ivacaftor to Treat People With Cystic Fibrosis 12 Years and Older With At Least One F508del Mutation in the CFTR Gene
11/19/2021
Vertex Pharmaceuticals Incorporated announced that the Spanish government has approved terms for the national reimbursement of KAFTRIO® in a combination regimen with ivacaftor for the treatment of cystic fibrosis for eligible patients.
-
Two weeks after Novartis announced it would sell its nearly one-third voting stake in next-door neighbor Roche, investors are chomping at the bit to find out how that almost $21 billion will be put to work.
-
Vertex Receives CHMP Positive Opinion for KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in Combination With Ivacaftor in Children With Cystic Fibrosis Ages 6 Through 11
11/12/2021
Vertex Receives CHMP Positive Opinion for KAFTRIO ® (ivacaftor/tezacaftor/elexacaftor) in Combination With Ivacaftor in Children With Cystic Fibrosis Ages 6 Through 11
-
Arbor announced an oversubscribed Series B raise totaling $215 million, a significant increase from their initial $15.6 milllion Series A round to test for liver and CNS diseases.
-
This first-of-its-kind collaboration will leverage the talent and innovation at companies such as Tessera Therapeutics to advance multiple candidates to human proof of concept.
-
Vertex Reports Third-Quarter 2021 Financial Results
11/2/2021
Vertex Pharmaceuticals Incorporated reported consolidated financial results for the third quarter ended September 30, 2021 and raised full-year 2021 product revenue guidance to $7.4 to $7.5 billion.
-
Mammoth Biosciences just announced a collaboration with Vertex to develop in vivo gene-editing therapeutics for patients with either of two serious, but not-yet-disclosed diseases.
-
Clinical Catch-Up: October 18-22
10/25/2021
It was yet another busy week for clinical trial news. Here’s a look. -
ReCode is aiming to advance its lead candidates for cystic fibrosis and primary ciliary dyskinesia (PCD).
-
Vertex Pharmaceuticals announced positive Day 90 data from the first patient in its Phase I/II study of VX-880 in type 1 diabetes.
-
The analysis showed a 52-week glucose remission rate of 65.2% among the 69 patients being followed.
-
Vertex's Supplement to a New Drug Submission for KALYDECO (ivacaftor) for Patients with Cystic Fibrosis Between the Ages of 4 Months and 18 Years with the R117H Mutation in the CFTR Gene Accepted for Priority Review by Health Canada
9/22/2021
Vertex Pharmaceuticals Incorporated today announced its Supplement to a New Drug Submission for Pr KALYDECO ® (ivacaftor) has been accepted for priority review by Health Canada for the treatment of cystic fibrosis
-
During the past two years, fundraising and investment in biotechnology have reached record levels.
-
Vertex Announces Letter of Intent With pan-Canadian Pharmaceutical Alliance for Public Reimbursement of CFTR Modulators Extended to Include TRIKAFTA(elexacaftor/tezacaftor/ivacaftor and ivacaftor)
9/17/2021
Vertex Pharmaceuticals Incorporated (Canada) (Nasdaq: VRTX) today announced that it has signed a Letter of Intent (LOI) with the pan-Canadian Pharmaceutical Alliance (pCPA), which represents an agreement in principle regarding the public reimbursement of PrTRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) for eligible patients with cystic fibrosis (CF).
-
Health Canada Grants Marketing Authorization for KALYDECO(ivacaftor) as First and Only CFTR Modulator to Treat Eligible Infants With CF as Early as Four Months of Age
8/25/2021
Vertex Pharmaceuticals Incorporated (Canada) (Nasdaq: VRTX) today announced that Health Canada has granted Marketing Authorization for PrKALYDECO®
-
With a handful of drugs for cystic fibrosis already approved, Vertex Pharmaceuticals has turned its attention to expanding its pipeline through collaborations and acquisitions the past few years.
-
With this milestone, the field is now wide open for the next in vivo CRISPR success, and Editas is hoping that it will be in the ocular disease space.
-
The company is eager to diversify, putting Phase II clinical trials in sickle-cell disease, beta-thalassemia, kidney diseases, and pain management.
-
Vertex Reports Second-Quarter 2021 Financial Results
7/29/2021
Vertex Pharmaceuticals Incorporated reported consolidated financial results for the second quarter ended June 30, 2021 and raised full-year 2021 guidance for product revenues to $7.2 to $7.4B.